Table 1.
Baseline characteristics of 251 molecularly characterized E2993 patients (excluding the 31 B-other patients), including patients who were not eligible for trial
| Molecular subgroup | Number of patients | % | Age (y) median (Q1, Q3) | WBC × 109/L median (Q1, Q3) | Sex (%), F/M |
|---|---|---|---|---|---|
| DUX4-R | 22 | 7.8 | 26.0 (22.5, 40.3) | 9.3 (3.5, 23.6) | 52.4/47.6 |
| ETV6-RUNX1/-like* | 5 | 1.8 | 22.0 (20.0, 26.0) | 6.7 (2.0, 9.7) | 60.0/40.0 |
| TCF3-PBX1 | 15 | 5.3 | 29.0 (22.5, 37.5) | 29.8 (10.4, 61.2) | 46.7/53.3 |
| KMT2A-AFF1 | 27 | 9.6 | 38.0 (32.0, 45.0) | 92.0 (43.4, 229.2) | 76.9/23.1 |
| KMT2A-non-AFF1 | 10 | 3.5 | 35.5 (31.5, 46.5) | 84.4 (6.1, 190.2) | 70/30 |
| PAX5alt | 27 | 9.6 | 38.0 (20.5, 50.0) | 9.2 (3.5, 23.5) | 18.5/81.5 |
| PAX5 P80R | 10 | 3.5 | 26.5 (20.8, 46.3) | 11.7 (3.9, 22.5) | 30/70 |
| Ph-like CRLF2-R | 30 | 10.6 | 28.0 (19.3, 35.8) | 23.3 (11.0, 70.8) | 20/80 |
| Ph-like non-CRLF2-R | 18 | 6.4 | 38.5 (30.0, 48.8) | 14.3 (6.1, 60.4) | 61.1/38.9 |
| ZNF384-R/-like* | 11 | 3.9 | 27.0 (26.0, 42.5) | 13.2 (6.2, 36.7) | 18.2/81.8 |
| MEF2D-R | 6 | 2.1 | 22.0 (19.0, 43.8) | 25.0 (10.0, 32.9) | 50.0/50.0 |
| BCL2/MYC | 12 | 4.3 | 40.0 (26.5, 48.8) | 28.5 (16.7, 57.8) | 36.4/63.6 |
| ZEB2/CEBPE | 4 | 1.4 | 43.0 (37.8, 45.8) | 32.6 (2.8, 86.9) | 50.0/50.0 |
| iAMP21 | 3 | 1.1 | 21.0 (20.0, 30.0) | 4.2 (3.9, 6.0) | 33.3/66.7 |
| TCF3-HLF | 1 | 0.4 | 44 (44, 44) | 6.1 (6.1, 6.1) | 100/0 |
| HH | 16 | 5.7 | 20.0 (18.0, 29.3) | 2.5 (1.9, 9.5) | 25/75 |
| LH/NH | 34 | 12.1 | 44.0 (36.0, 53.0) | 3.7 (2.9, 7.6) | 37.1/62.9 |
F, female; M, male.
*
Combination of patients who were ETV6-RUNX1 and ETV6-RUNX1-like, as well as ZNF384 and ZNF384-like.